China Regenerative Medicine Market Size & Outlook
China regenerative medicine market, 2018-2030 (US$M)
Related Markets
China regenerative medicine market highlights
- The China regenerative medicine market generated a revenue of USD 980.1 million in 2023 and is expected to reach USD 2,572.2 million by 2030.
- The China market is expected to grow at a CAGR of 14.8% from 2024 to 2030.
- In terms of segment, therapeutics was the largest revenue generating product in 2023.
- Banks is the most lucrative product segment registering the fastest growth during the forecast period.
Regenerative medicine market data book summary
| Market revenue in 2023 | USD 980.1 million |
| Market revenue in 2030 | USD 2,572.2 million |
| Growth rate | 14.8% (CAGR from 2023 to 2030) |
| Largest segment | Therapeutics |
| Fastest growing segment | Banks |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Therapeutics, Tools, Banks, Services |
| Key market players worldwide | AstraZeneca PLC, Roche Holding AG, Integra Lifesciences Holdings Corp, Astellas Pharma Inc, Cook Group, Bayer AG, Pfizer Inc, Merck KGaA, Abbott Laboratories, Vericel Corp, Novartis AG ADR, GlaxoSmithKline |
Other key industry trends
- In terms of revenue, China accounted for 3.2% of the global regenerative medicine market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan regenerative medicine market is projected to lead the regional market in terms of revenue in 2030.
- South Korea is the fastest growing regional market in Asia Pacific and is projected to reach USD 1,288.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Regenerative Medicine Market Scope
Regenerative Medicine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China regenerative medicine market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to regenerative medicine market will help companies and investors design strategic landscapes.
Therapeutics was the largest segment with a revenue share of 76.77% in 2023. Horizon Databook has segmented the China regenerative medicine market based on therapeutics, tools, banks, services covering the revenue growth of each sub-segment from 2018 to 2030.
China's regenerative medicine market is anticipated to witness significant growth over the forecast period due to increasing demand for cell and gene therapy. The companies and authorities operating in the country are focusing on cell and gene therapy. For instance, in August 2023, China’s National Medical Products Administration (NMPA) approved an Investigational New Drug (IND) application for OriCAR-017 from Oricell Therapeutics.
This authorized it to study autologous CAR T-cell therapy for patients suffering from advanced multiple myeloma. Thus, such increasing emphasis on cell therapies in the market is anticipated to fuel the regenerative medicine market growth.
Reasons to subscribe to China regenerative medicine market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China regenerative medicine market databook
-
Our clientele includes a mix of regenerative medicine market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China regenerative medicine market , including forecasts for subscribers. This country databook contains high-level insights into China regenerative medicine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
China regenerative medicine market size, by product, 2018-2030 (US$M)
China Regenerative Medicine Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
